(S)-4-(tert-butoxy)-2-cyclopropyl-4-oxobutanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-4-(tert-butoxy)-2-cyclopropyl-4-oxobutanoic acid
• 英文别名: (2S)-2-cyclopropyl-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
• 化学式: C₁₁H₁₈O₄
• 分子量: 214.262
• InChiKey: YKHQTIZYPWUPQR-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-4-(tert-butoxy)-2-cyclopropyl-4-oxobutanoic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 吡啶 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 (S)-3-cyclopropyl-4-(((S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)-4-oxobutanoic acid
  参考文献：
  名称：

  Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo

  摘要：

  Signal peptide peptidase-like 2a (SPPL2a) is an aspartic intramembrane protease which has recently been shown to play an important role in the development and function of antigen presenting cells such as B lymphocytes and dendritic cells. In this paper, we describe the discovery of the first selective and orally active SPPL2a inhibitor (S)-2-cyclopropyl-N1-((S)-5,11-dioxo-10,11-dihydro-1H,3H,5H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropan]-10-yl)-N4-(5-fluoro-2-methylpyridin-3-yl)succinamide 40 (SPL-707). This compound shows adequate selectivity against the closely related enzymes gamma-secretase and SPP and a good pharmacokinetic profile in mouse and rat. Compound 40 significantly inhibited processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses <= 10 mg/kg b.i.d. po. Oral dosing of 40 for 11 days at >= 10 mg/kg b.i.d. recapitulated the phenotype seen in Sppl2a knockout (ko) and ENU mutant mice (reduced number of specific B cells and myeloid dendritic cells). Thus, we believe that SPPL2a represents an interesting and druggable pharmacological target, potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.

  DOI：

  10.1021/acs.jmedchem.7b01371
• 作为产物：
  描述：

  环丙乙酸 在 4-二甲氨基吡啶 、 双氧水 、 sodium hexamethyldisilazane 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 20.0h， 生成 (S)-4-(tert-butoxy)-2-cyclopropyl-4-oxobutanoic acid
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS
  [FR] COMPOSÉS ET COMPOSITIONS SERVANT D'INHIBITEURS DE SPPL2A

  摘要：

  本发明涉及三环化合物，包括一种二氮杂环酮基团，其能够有效抑制Sppl2a（信号肽酶类蛋白酶2a），以及含有这种抑制剂的制药组合物，以及使用这种抑制剂和组合物的方法。

  公开号：

  WO2022058902A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS SERVANT D'INHIBITEURS DE SPPL2A
  申请人：NOVARTIS AG

  公开号：WO2022058902A1

  公开（公告）日：2022-03-24

  The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.

  本发明涉及三环化合物，包括一种二氮杂环酮基团，其能够有效抑制Sppl2a（信号肽酶类蛋白酶2a），以及含有这种抑制剂的制药组合物，以及使用这种抑制剂和组合物的方法。
• ANTIVIRAL COMPOUNDS
  申请人：Cottell Jeromy J.

  公开号：US20140051626A1

  公开（公告）日：2014-02-20

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的过程和中间体。
• US8513186B2
  申请人：——

  公开号：US8513186B2

  公开（公告）日：2013-08-20
• Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo
  作者：Juraj Velcicky、Ursula Bodendorf、Pascal Rigollier、Robert Epple、Daniel R. Beisner、Danilo Guerini、Philip Smith、Bo Liu、Roland Feifel、Peter Wipfli、Reiner Aichholz、Philippe Couttet、Ina Dix、Toni Widmer、Ben Wen、Trixi Brandl

  DOI：10.1021/acs.jmedchem.7b01371

  日期：2018.2.8

  Signal peptide peptidase-like 2a (SPPL2a) is an aspartic intramembrane protease which has recently been shown to play an important role in the development and function of antigen presenting cells such as B lymphocytes and dendritic cells. In this paper, we describe the discovery of the first selective and orally active SPPL2a inhibitor (S)-2-cyclopropyl-N1-((S)-5,11-dioxo-10,11-dihydro-1H,3H,5H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropan]-10-yl)-N4-(5-fluoro-2-methylpyridin-3-yl)succinamide 40 (SPL-707). This compound shows adequate selectivity against the closely related enzymes gamma-secretase and SPP and a good pharmacokinetic profile in mouse and rat. Compound 40 significantly inhibited processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses <= 10 mg/kg b.i.d. po. Oral dosing of 40 for 11 days at >= 10 mg/kg b.i.d. recapitulated the phenotype seen in Sppl2a knockout (ko) and ENU mutant mice (reduced number of specific B cells and myeloid dendritic cells). Thus, we believe that SPPL2a represents an interesting and druggable pharmacological target, potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.